INTRODUCTION
Despite prophylactic immunosuppression (IST) and improvements in high-resolution HLA typing, acute GVHD (aGVHD) remains the major early complication following allogeneic hematopoietic cell transplantation (HCT). High-dose corticosteroids are the established first-line treatment of moderate-to-severe aGVHD; 1 however, only 50-60% of patients will achieve a complete response to frontline therapy with steroids. 2 Incomplete responses and recurrent aGVHD symptoms are common with steroids, thus indicating a need for improved treatment options. Furthermore, there is no established second-line therapy for steroid-refractory aGVHD. Welldesigned clinical trials with validated end points for treatment success are needed to rigorously examine new therapies to improve aGVHD outcomes. 3 At present, the optimal end points for aGVHD clinical trials have not been established, thus interfering with the ability to identify and compare novel regimens for aGVHD treatment.
Emerging data indicates that aGVHD response after 28 days of treatment could be an important early end point for assessing therapeutic success in aGVHD clinical trials. 2, 4, 5 Although the day 28 response appears to be a valid proximal predictor of more distal outcomes, there are several important limitations associated with this marker. First, day 28 response as determined by rash, persistent anorexia/nausea, quantity of diarrhea and serum bilirubin concentration can be affected by non-GVHD factors including infections, medications or organ dysfunction related to conditioning (i.e., hepatic veno-occlusive disease/sinusoidal obstruction syndrome). In addition, grading of aGVHD and determining clinical response to treatment can be associated with interobserver variation, which could be problematic for multicenter clinical trials. The American Society for Blood and Marrow Transplantation (ASBMT) has proposed the 6-month (m) freedom from treatment failure (FFTF) as a primary end point to gauge treatment efficacy in aGVHD clinical trials. The ABSMT 6-m FFTF is not directly determined by clinical response and is instead defined by the absence of death, malignancy relapse/progression or systemic IST change within 6 months of starting initial treatment and before chronic GVHD (cGVHD) diagnosis. 1, 6 The association of 6-m FFTF with important clinical characteristics and transplant outcomes is currently unknown. We hypothesize that the ASBMT 6-m FFTF will be associated with the day 28 response and that the 6-m FFTF can predict long-term therapeutic success in patients with aGVHD requiring treatment without the associated limitations inherent with the more commonly used day 28 clinical response.
MATERIALS AND METHODS Patients
From February 2007 to March 2009, 100 adult patients with hematological malignancies received myeloablative or reduced intensity conditioning followed by a T-cell replete matched-related or -unrelated donor HCT at Vanderbilt University Medical Center. Seventy-four of these individuals were enrolled in a prospective biomarker clinical trial. 7 Within 100 days of transplant, 45 (61%) HCT recipients developed aGVHD requiring treatment with systemic steroids. One patient was excluded owing to malignancy progression before steroid treatment. Thus, 44 patients were included in the final analysis. The study protocol was reviewed and approved by the Human Subject Institutional Review Board at Vanderbilt University Medical Center. Signed informed consent was obtained.
All patients received GVHD prophylaxis with a calcineurin inhibitor and either methotrexate or mycophenolate mofetil. Patients receiving T-cell depletion with thymoglobulin were excluded from the original clinical trial. Only one patient received a DLI for relapsed malignancy during the study period. aGVHD was diagnosed clinically and was confirmed by biopsy in all patients. Clinical features of aGVHD or cGVHD were assessed weekly for the first 100 days after HCT. Thereafter, GVHD status was updated at least monthly during visits to the long-term transplant clinic or at the time of acute hospitalizations. The recorded features included aGVHD or cGVHD incidence, organ involvement, severity, recurrence rates and response to treatment. The clinical severity of aGVHD was determined by the overall grade (0-4) and the individual organ stage (0-4), as defined by the 1994 consensus conference criteria. 8 cGVHD diagnosis and severity was determined as per 2005 National Institutes of Health consensus guidelines. 9 aGVHD therapy and response Patients with moderate-to-severe aGVHD were treated with high-dose corticosteroids (1-2 mg/kg per day of i.v. methylprednisolone or oral prednisone) as per the institutional guidelines for 7-10 days, followed by a standard taper of 10% every 5-7 days. Secondary aGVHD therapy was administered to patients as per the standard of care practice within our institutional guidelines for (1) aGVHD progression after 3 days of high-dose corticosteroids, (2) no response after 7 days of corticosteroids or (3) aGVHD flare while on corticosteroids and after initial response to treatment. Generally, extracorporeal photopheresis was used as the standard second-line treatment for aGVHD at our institution. Rituximab or TNF blockade was added to extracorporeal photopheresis for severe skin or gut aGVHD, respectively, or they were used as primary therapy if extracorporeal photopheresis was contraindicated (i.e., medically unstable patient, inability to place pheresis catheter due to active bacteremia, etc.).
Patients were followed up for 6 months after the start of steroids. aGVHD response to systemic steroids at day 28 after treatment initiation was classified as complete response (CR), very good partial response (VGPR), partial response (PR) and no response (NR) as previously defined by the ASBMT joint statement and modified by Macmillan et al. 2 Table 1 ). 10 Six-month treatment failure was defined as per the recent ASBMT consensus as follows: death from any cause, relapse or progression of malignancy, or change in systemic IST within 180 days of starting steroid therapy and before cGVHD diagnosis. 1, 6 During analysis, patients meeting the criteria for 6-m treatment failure were counted only once irrespective of the number of failure events they experienced. Triamcinolone cream and psoralen with ultraviolet A therapy (PUVA) were not considered systemic IST and when added to primary therapy were not counted as steroid failure events. cGVHD development was treated as a competing risk for 6-m aGVHD steroid failure.
(Supplementary

Statistical analysis
OS was estimated using the Kaplan-Meier method and cumulative incidence was used to estimate the probability of non-relapse mortality (NRM) and 6-m treatment failure. OS and NRM were calculated from the initiation of steroid therapy. NRM was defined as death in the absence of disease relapse or progression. Relapse was considered a competing risk for NRM. Time to 6-m treatment failure was defined as the date from steroid initiation to 6 months of follow-up or the first of the following events: death, malignancy relapse/progression or initiation of second-line systemic treatment for aGVHD. Patient data were censored at the time of cGVHD if diagnosis occurred during the first 180 days of steroid treatment for aGVHD. Survival outcomes between groups were compared with a logrank test for univariate analysis and a Cox proportional hazards regression for multivariate analysis. Nominal variables were described by the percentage or frequency and were compared by the w 2 or Fisher's exact test. McNemar's test was used to compare the proportion of patients in a group before and after an intervention. P-values were two-tailed and considered significant at Po0.05. Analyses were performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA) and R version 2.7.0 (Free Software Foundation, Boston, MA, USA).
RESULTS
Patients
Response to systemic corticosteroids was assessed in 44 evaluable patients with aGVHD (grade 1 (N ¼ 2), grade 2 (N ¼ 30), grade 3-4 (N ¼ 12)). Two patients with grade 1 aGVHD were treated with systemic steroids for rapid progression of skin rash despite topical therapy with triamcinolone cream. Clinical characteristics of the cohort are outlined in Table 1 . The median time to aGVHD and initiation of steroid therapy after HCT was 24 days (range, 7-56) and 28 days (range, 7-91), respectively. Skin only, gut only and multiorgan aGVHD affected 7 (16%), 19 (43%) and 18 (41%) patients, respectively. aGVHD treatment response Day 28 response to steroids was CR (N ¼ 14 (32%)), VGPR (N ¼ 7 (16%)), PR (N ¼ 17 (39%)) and NR (N ¼ 6 (13%)). The probability of achieving 6-m FFTF was 61% (95% confidence interval (CI), 0.46-0.76) for the entire cohort. Thus, 38 (87%) patients responded (CR þ VGPR þ PR) to treatment by day 28 after steroid initiation, but only 28 (64%) patients met the 6-m FFTF end point. The causes for treatment failure are described in Figure 1 . cGVHD developed in 11 (25%) patients during the first 6 months of treatment, but only 1 of these individuals had a failure event censored for cGVHD diagnosis before IST change. The most common indication for 6-m treatment failure was the addition of new IST (11 out of 16 treatment failure events), occurring at a median of 37 days (range, 4-160) after starting steroids. Indications for adding second line-therapy were progressive aGVHD after 3 days of high-dose steroids (N ¼ 3), no response after 7 days of high-dose steroids (N ¼ 1) or aGVHD flare while on steroids and after initial response to treatment (N ¼ 7). Among patients with changes in systemic IST, seven had initially responded to treatment by day 28 but had recurrent aGVHD symptoms during the steroid taper. Specifically, three patients had a flare of aGVHD 4100 days after the start of steroids, requiring second-line therapy. The type and number of second-line agents used to treat aGVHD after steroid failure varied and therapies included: extracorporeal photopheresis (N ¼ 8), TNF-a blockade (N ¼ 4) and rituximab (N ¼ 3). The remaining steroid failure events were not associated with changes in IST and were attributed to four patients with malignancy relapse and one patient death while in remission ( Figure 1 ).
As expected, day 28 NR was significantly associated with treatment failure at 6 months (P ¼ 0.01) ( Table 1 ). In addition, grade 3-4 aGVHD tended to be more common in patients categorized as 6-m treatment failures (7 out of 16 patients (44%)) as compared with HCT recipients with 6-m FFTF (5 out of 28 individuals (18%)) (P ¼ 0.06). No other clinical variables outlined in Table 1 were associated with 6-m FFTF.
Survival
The median follow-up for surviving patients (N ¼ 29) was 3 years (range, 0.5-4 years). Death from relapse and NRM occurred in eight (18%) and seven (16%) individuals, respectively. Causes of NRM included: infection (N ¼ 2), bronchiolitis obliterans (N ¼ 2), aGVHD (N ¼ 1), diffuse alveolar hemorrhage (N ¼ 1) and secondary malignancy (N ¼ 1). Transplant outcomes were improved in patients responding to steroids (CR þ VGPR þ PR) when compared with those with NR at day 28 (2-year OS of 75% (95% CI, 0.58-0.86) vs 22% (95% CI, 0.01-0.62), P ¼ 0.02 and 2-year NRM of 11% (95% CI, 0.04-0.30) vs 73% (95% CI, 0.31-0.99), P ¼ 0.01). FFTF at 6 months was associated with superior 2-year OS (81% (95% CI, 0.61-0.92) vs 48% (95% CI, 0.22-0.70), P ¼ 0.03) and decreased NRM (8% (95% CI, 0.02-0.29) vs 49% (95% CI, 0.22-0.84), P ¼ 0.01) when compared with individuals failing steroids by 6 months (Figure 2 ). To replicate a therapeutic aGVHD clinical trial, analyses End points for acute GVHD clinical trials S Sengsayadeth et al were repeated using only patients with grade 2-4 aGVHD (N ¼ 42). Results were unchanged after excluding the two individuals with grade 1 aGVHD with a 2-year OS of 85% (95% CI, 0.71-0.99) vs 48% (95% CI, 0.22-0.73) (P ¼ 0.03) and 2-year NRM of 8% (95% CI, 0.03-0.19) vs 49% (95% CI, 0.14-0.84) (P ¼ 0.02) for HCT recipients with FFTF contrasted with those with failure at 6 months, respectively. To minimize heterogeneity, a subset analysis was also performed using only patients with related donors (N ¼ 23). All of these transplants were HLA identical and all patients received mobilized PBSCs except 1 individual. Among patients with matched-related donors, OS at 2 years was 80% (95% CI, 0.60-0.99) for those with FFTF at 6 months and 38% (95% CI, 0.04-0.72) for treatment failures (P ¼ 0.04), similar to the results using the entire cohort.
Prolonged exposure to high-dose corticosteroids can have detrimental health outcomes. Therefore, we modified the original ASBMT criteria for 6-m FFTF to include 10 additional patients who had an increase in steroid dosage within 6 months of starting initial treatment or who had steroid doses X0.25 mg/kg 180 days after beginning treatment, but this did not improve the predictive power of the end point (OS (P ¼ 0.17) or NRM (P ¼ 0.23)).
Multivariate analysis
After adjusting for important clinical variables including recipient age, disease risk, conditioning regimen intensity, donor type and stem cell source, the 6-m FFTF continued to be associated with improved OS (hazard ratio, 0.27; 95% CI, 0.08-0.85; P ¼ 0.03) and decreased NRM (hazard ratio, 0.02; 95% CI, 0.01-0.39; P ¼ 0.01) ( Table 2) .
DISCUSSION
We studied the 6-m FFTF as recently proposed by Martin and coworkers 1,6 as a potential clinical trial end point for determining aGVHD treatment success. The 6-m FFTF was found to be an important marker of therapeutic efficacy that was associated with both improved OS and decreased NRM in patients receiving T-cell replete transplants. The primary implication of this end point is that the necessity of changing aGVHD therapy results from suboptimal response to initial treatment, which ultimately increases the risk for adverse outcomes. It also takes into account that most deaths related to uncontrolled aGVHD or from infections due to excessive immunosuppression occur within 6 months and that longer follow-up may be confounded by recurrent malignancy or cGVHD. 6 The advantage to this end point End points for acute GVHD clinical trials S Sengsayadeth et al is its inherent reduction of subjectivity by assessing fixed outcomes including: death, relapse or change in systemic IST within 6 months of steroid initiation and before the development of cGVHD.
To investigate whether expanding the 6-m FFTF definition could further enhance the prediction of outcomes, we added the following end points: (1) any increase in steroids within 180 days, or (2) a steroid dose X0.25 mg/kg per day at 180 days after initiation of therapy as additional markers of treatment failure. In our limited sample size, these supplementary end points were not statistically significant. However, there may be value in studying this expanded definition of 6-m steroid failure in a larger cohort of patients.
Our study also showed that day 28 response predicted treatment failure at 6 months as defined by the ASBMT criteria. Levine et al. 5 first examined whether response to aGVHD treatment predicted outcomes by analyzing time to response at days 14, 28 and 56 in a phase II trial that consisted of initial therapy with high-dose steroids plus a second immunosuppressive agent. Although all three response time-points showed utility in predicting outcomes, they particularly identified that day 28 CR or PR was most predictive of OS and NRM after 9 months from initiation of treatment. 5 Day 28 response to initial steroid therapy has been further studied by MacMillan et al. 2 and Saliba et al., 4 and their results suggest that the day 28 response is also likely the best early end point. Our data are consistent with these studies in that OS and cumulative incidence of NRM at 2 years was significantly improved in steroid responders at day 28 (CR þ VGPR þ PR) when compared with those with NR.
For aGVHD, day 28 response may be inadequate to fully measure treatment efficacy, specifically in a clinical trial setting. A major limitation of this end point is its dependence on accurately measuring clinical response to aGVHD treatment, which is subject to interobserver variation. Furthermore, response to aGVHD End points for acute GVHD clinical trials S Sengsayadeth et al treatment is usually based on measuring clinical variables including: body surface area involved by rash, volume of diarrhea and liver function tests. These parameters can be affected by a variety of other etiologies unrelated to alloreactivity such as medications, and thus confound the aGVHD response assessment. The advantage to the 6-m FFTF is that it assesses fixed end points and is therefore less affected by these problems. The composite 6m FFTF end point also evaluates other important clinical outcomes that could be affected by aGVHD therapy including death and relapse, which are not directly measured by the day 28 response criteria. It is possible that an extremely effective immunosuppressant, which induces high rates of response could be associated with undesirable consequences including increased risk for fatal infections or increased incidence of relapses due to impaired GVL effect. Clinical trials will need to account for both the positive and negative outcomes associated with therapy that effectively suppresses aGVHD. This present study is limited by patient heterogeneity and a small sample size. As with previous aGVHD trials, other parameters such as variability in initial steroid doses, duration of therapy and steroid tapering schedules are confounding issues that are difficult to account for. On the other hand, this was a prospective clinical trial with weekly blinded assessment of aGVHD parameters. Despite the modest sample size and heterogeneous cohort, we have shown that the 6-m FFTF predicted survival and confirmed previous data regarding day 28 response, indicating that these are robust end points even in small cohorts. The predominance of gut aGVHD could suggest underdiagnosis of skin aGVHD; however, even if cutaneous involvement was underdiagnosed, the clinical significance is questionable since it did not meet the threshold for treatment with systemic steroids and therefore should not affect the current analysis. In addition, our results pertain only to patients undergoing T-cell replete transplants as individuals receiving manipulated grafts or thymoglobulin were excluded. aGVHD causes significant morbidity and mortality. Despite this, no therapeutic agent has obtained Food and Drug administration approval for the treatment of aGVHD. This is due in part to the lack of standardized end points in aGVHD clinical trials. Therefore, establishing accepted markers of effective aGVHD treatment, which also serve as surrogates measures of long-term transplant survival, is of paramount significance for aGVHD trials. Our data indicate that 6-m FFTF is associated with day 28 response and both are predictive of transplant outcomes. However, 6-m FFTF that assesses fixed outcomes is less affected by the limitations and the variability associated with determining clinical response to aGVHD therapy. If validated, the 6-m FFTF could be used as the primary end point in future therapeutic aGVHD trials and subsequently facilitate approval of new therapies for aGVHD treatment.
